1. Signaling Pathways
  2. Cell Cycle/DNA Damage
  3. SRPK
  4. SRPK Inhibitor

SRPK Inhibitor

SRPK Inhibitors (9):

Cat. No. Product Name Effect Purity
  • HY-117661
    SPHINX31
    Inhibitor 99.13%
    SPHINX31 is a potent and selective SRPK1 inhibitor, with an IC50 of 5.9 nM. SPHINX31 inhibits phosphorylation of serine/arginine-rich splicing factor 1 (SRSF1). SPHINX31 also decreases the mRNA expression of pro-angiogenic VEGF-A165a isoform. SPHINX31 can be used to research neovascular eye disease.
  • HY-13949
    SRPIN340
    Inhibitor 99.97%
    SRPIN340 is an ATP-competitive serine-arginine-rich protein kinase (SRPK) inhibitor, with a Ki of 0.89 μM for SRPK1.
  • HY-116856
    SRPKIN-1
    Inhibitor 98.02%
    SRPKIN-1 is a covalent and irreversible SRPK1/2 inhibitor with IC50s of 35.6 and 98 nM, respectively. Anti-angiogenesis effect.
  • HY-148518
    MSC-1186
    Inhibitor 99.42%
    MSC-1186 is a highly selective pan-SRPK inhibitor. MSC-1186 has activity for SRPK1, SRPK2 and SRPK3 with IC50 values of 2.7 nM, 81 nM and 0.6 nM, respectively. MSC-1186 can be used for the research of cancer.
  • HY-114653
    SRPIN803
    Inhibitor 99.17%
    SRPIN803 is a potent CK2 and SRPK1 dual inhibitor, with IC50s of 203 nM and 2.4 μM, respectively. SRPIN803 exhibits antiangiogenic activity. SRPIN803 can be used for the research of age-related macular degeneration.
  • HY-160587
    Antiangiogenic agent 5
    Inhibitor
    Antiangiogenic agent 5 (compound 17) has anti-angiogenic activity. Antiangiogenic agent 5 show inhibition to SRPK1, with IC50 of 1.3 nM.
  • HY-160586
    Srpk1-IN-1
    Inhibitor
    Srpk1-IN-1 (compound 12) is a potent inhibitor of SRPK1, with IC50 of 0.3 nM.
  • HY-132126
    SPHINX
    Inhibitor 99.87%
    SPHINX is a selective SRPK1 inhibitor with an IC50 value of 0.58 μM. SPHINX effectively reduces Choroidal Neovascularization (CNV) in vivo. SPHINX can be used for the research of (age-related macular degenaration) AMD.
  • HY-113831
    CLK1/2-IN-3
    Inhibitor
    LK1/2-IN-3 (compound 3) is a potent and selective CLK1 and CLK2 inhibitor with IC50 values of 1.1, 2.1, 130, 260, 260 nM for CLK1, CLK2, SRPK1, SRPK2, SRPK3, respectively. CLK1/2-IN-3 shows anti-proliferative activity. CLK1/2-IN-3 reduces the levels of endogenous phosphorylated SR proteins and increases the expression of S6K mRNAs.